Opinion|Videos|April 18, 2025
The Role of Continuing Cemiplimab in Second-Line Therapy After Progression
Author(s)Eric K. Singhi, M.D., Ben Creelan, M.D.
Panelists discuss how, cemiplimab, a PD-1 inhibitor, has shown promise as a second-line therapy for advanced NSCLC after progression on prior treatments. Continuing cemiplimab post-progression can enhance survival outcomes by maintaining immune system activation against cancer cells.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the role of continuing cemiplimab in second-line therapy after progression.
Advertisement
Related to this article
γδ T cells infiltrate small cell lung cancer tumors and can kill them without the MHC-I machinery these tumors typically switch off, and patients with more of them trended toward longer survival on anti-PD-L1 immunotherapy.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Six jobs for AI in myeloma care, from Prerna Mewawalla, M.D.
2
Vaccine schedule overhaul could put coverage at risk, state official says
3
Bronchiectasis is more common in the U.S. than a decade ago, study finds
4
Patience and persistence define one Yale gastroenterologist’s approach to MASLD
5